Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

H.S. Rugo, K. Jhaveri, S. Pernas, B. Pistilli, S.-A. Im, M. De Laurentiis, S. Wang, N. Martínez Jañez, G. Borges, D.W. Cescon, M. Hattori, Y.-S. Lu, E. Hamilton, Q. Zhang, J. Tsurutani, K. Kalinsky, P.E. Rubini Liedke, Z. Nowecki, S.M. Tolaney, K. Zhao, K. Atuah, D. Verma, B. Xu, A. Bardia

Open source

DOI: 10.1016/j.esmoop.2026.108330
Published: 2026-08
Container: ESMO Open
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.108330,
  title = {Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study},
  author = {H.S. Rugo and K. Jhaveri and S. Pernas and B. Pistilli and S.-A. Im and M. De Laurentiis and S. Wang and N. Martínez Jañez and G. Borges and D.W. Cescon and M. Hattori and Y.-S. Lu and E. Hamilton and Q. Zhang and J. Tsurutani and K. Kalinsky and P.E. Rubini Liedke and Z. Nowecki and S.M. Tolaney and K. Zhao and K. Atuah and D. Verma and B. Xu and A. Bardia},
  year = {2026},
  journal = {ESMO Open},
  doi = {10.1016/j.esmoop.2026.108330},
  url = {https://doi.org/10.1016/j.esmoop.2026.108330}
}

RIS

TY  - JOUR
TI  - Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study
AU  - H.S. Rugo
AU  - K. Jhaveri
AU  - S. Pernas
AU  - B. Pistilli
AU  - S.-A. Im
AU  - M. De Laurentiis
AU  - S. Wang
AU  - N. Martínez Jañez
AU  - G. Borges
AU  - D.W. Cescon
AU  - M. Hattori
AU  - Y.-S. Lu
AU  - E. Hamilton
AU  - Q. Zhang
AU  - J. Tsurutani
AU  - K. Kalinsky
AU  - P.E. Rubini Liedke
AU  - Z. Nowecki
AU  - S.M. Tolaney
AU  - K. Zhao
AU  - K. Atuah
AU  - D. Verma
AU  - B. Xu
AU  - A. Bardia
PY  - 2026
JO  - ESMO Open
DO  - 10.1016/j.esmoop.2026.108330
UR  - https://doi.org/10.1016/j.esmoop.2026.108330
ER  -

APA

Rugo, H., Jhaveri, K., Pernas, S., Pistilli, B., Im, S., Laurentiis, M. D., Wang, S., Jañez, N. M., Borges, G., Cescon, D., Hattori, M., Lu, Y., Hamilton, E., Zhang, Q., Tsurutani, J., Kalinsky, K., Liedke, P. R., Nowecki, Z., Tolaney, S., Zhao, K., Atuah, K., Verma, D., Xu, B., & Bardia, A. (2026). Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.108330

Source records

crossref · retrieved 2026-09-25T17:07:30.807Z